Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model
Figure 1
Abeta aggregation prior to plaque formation in APP[V717I] (APP-Ld) and mice. (a) Representative photo collection of anti-Abeta stained sections showing total plaque load in APP-Ld mice of different ages (proprietary anti-Abeta Nanobody, reMYND/Ablynx, Belgium). (b) Aggregated Abeta in APP-Ld mice of different ages, both in preplaque (indicated by the dashed line) and postplaque stages of the Alzheimer pathology (-assay, Amorfix Life Sciences Ltd., Mississauga, Canada). The signal of nontransgenic mice was under the S/N cutoff value (data not shown). (c) As in B, for the model. The signal of nontransgenic mice was under the S/N cutoff value (data not shown).
